Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 16,542 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Connective Tissue Disease Clear all

Conditions: Dermatomyositis, Polymyositis
Interventions: Adrenocorticotropic Hormone Gel; Drug
Lead sponsor: Rohit Aggarwal, MD; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Great Neck, New York • Pittsburgh, Pennsylvania

Conditions: Acne Vulgaris
Interventions: SB204 4%, SB204 8% or 12%, Vehicle; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Breast Cancer
Interventions: Aerobic Training, Educational Information, Supervised Home Based Training; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 80 Years · Female only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Onychomycosis
Interventions: AN2690, AN2690 Solution, Vehicle, Sodium Lauryl Sulfate, 0.5%; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Lynchburg, Virginia

Conditions: Breast Cancer
Interventions: Inavolisib, Ribociclib, Fulvestrant, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 11
States / cities: Anaheim, California • Palo Alto, California • Jacksonville, Florida + 8 more

Conditions: Atopic Dermatitis
Interventions: Demonstration of applying triamcinolone cream, Mobile App Use, Standard of Care; Other · Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 9 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Scleroderma
Interventions: Not listed
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Cancer
Interventions: YM155, Docetaxel; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 7
States / cities: Los Angeles, California • Pleasant Hill, California • Lakeland, Florida + 4 more

Conditions: Hematopoietic Stem Cell Transplantation, Breast Cancer, Fatigue, Mild Cognitive Impairment, Light, Quality of Life, Sleep
Interventions: Bright white light, Dim red light; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Hackensack, New Jersey • New York, New York

Conditions: Plaque Psoriasis
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 40 more

Conditions: Breast Cancer
Interventions: Pain Coping Skills Training (PCST); Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 55 Years and older · Female only
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Mental Health Issue, Breast Cancer
Interventions: Digital Micro-Interventions; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Breast Cancer
Interventions: lapatinib ditosylate, Doxil; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Verruca Vulgaris, Warts, Common Wart
Interventions: VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch; Drug
Lead sponsor: Veradermics, Inc.; Industry
Eligibility: 9 Years to 65 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 16
States / cities: Fort Smith, Arkansas • San Diego, California • Plainfield, Indiana + 13 more

Conditions: Lice Infestations
Interventions: MALG; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 6 Months to 24 Months
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 5
States / cities: Scottsdale, Arizona • St. Petersburg, Florida • West Palm Beach, Florida + 2 more

Conditions: Skin Cancer
Interventions: Semi-tailored newsletter; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 5 Years to 6 Years
Enrollment: 867 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Breast Cancer Female
Interventions: tamoxifen, letrozole, anastrozole, or exemestane, Patient reported outcomes; Drug · Behavioral
Lead sponsor: Shayna Showalter, MD; Other
Eligibility: 65 Years and older · Female only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Charlottesville, Virginia • Richmond, Virginia

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Carboplatin, Computed Tomography, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Nab-paclitaxel, Personalized Synthetic Long Peptide Vaccine, Poly ICLC, Sacituzumab Govitecan, Tremelimumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 30
States / cities: Orange, California • Sacramento, California • Aurora, Colorado + 22 more

Conditions: Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Leiomyosarcoma, Liposarcoma, Angiosarcoma, Synovial Sarcoma, Rhabdomyosarcoma, Spindle Cell Sarcoma, High Grade Sarcoma, Bone Sarcoma, Osteosarcoma, Ewing Sarcoma of Bone
Interventions: Gemcitabine, 9-ING-41, Docetaxel; Drug
Lead sponsor: Brown University; Other
Eligibility: 10 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Breast Cancer
Interventions: Intraoperative radiotherapy, Intraoperative radiotherapy; Radiation · Device
Lead sponsor: University of Southern California; Other
Eligibility: 40 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rheumatoid Arthritis
Interventions: Ticagrelor, MTX therapy; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Breast Cancer Female, Cancer of Breast
Interventions: Bupivacaine, Gabapentin, Celecoxib, Acetaminophen, Midazolam, Fentanyl; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus Cream, 1%, Placebo Cream; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 8 Years and older
Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 25
States / cities: Boynton Beach, Florida • Coral Gables, Florida • Miami, Florida + 21 more

Conditions: Scabies
Interventions: Spinosad Topical; Drug
Lead sponsor: Cipher Pharmaceuticals Inc.; Industry
Eligibility: 1 Month to 4 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Miami, Florida • Lafayette, Louisiana • Houston, Texas

Search by objective public record fields.

Acthar in Treatment of Refractory Dermatomyositis and Polymyositis

A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204

Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer

Cumulative Irritation Test

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Topical Treatment for Atopic Dermatitis

The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)

A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer

Treating Cancer-Related Fatigue Through Systematic Light Exposure

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Behavioral Pain Intervention for Older Cancer Patients

Evaluating Digital Micro-Interventions to Reduce Distress and Increase Wellbeing in Breast Cancer Survivors

Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer

Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice

Skin Cancer Prevention in a Pediatric Population

Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast

Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis

PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery

Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis

PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies